Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
Key Highlights
- ➤Climb Bio (CLYM) will present new budoprutug ITP data at ASH December 13, 2026
- ➤Phase 1b presentation includes safety, B-cell depletion, and platelet data across three dose cohorts
- ➤Budoprutug is being evaluated in clinical trials for ITP, pMN, and SLE
- ➤Climb Bio is developing CLYM116, an anti-APRIL antibody for IgA nephropathy
WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for budoprutug in immune thrombocytopenia (ITP) at the 68(th) American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, Louisiana from December 12-15, 2026.
Climb Bio will present data, including safety, B-cell depletion, and platelet data from all three dose cohorts from the ongoing Phase 1b trial of budoprutug, a novel anti-CD19 monoclonal antibody, in previously treated patients with primary immune thrombocytopenia.
Get started
Create a free account to read the full story.